Suche   Â
Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
ID: 1546321
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Cancellation of publicly held Actelion shares and delisting from SIX Swiss
Exchange as of November 7, 2017
. Verarbeitet und übermittelt durch Nasdaq Corporate Solutions.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
Source: Globenewswire
ALLSCHWIL/BASEL, SWITZERLAND - October 31, 2017 - By decision dated October 25,
2017, the Cantonal Court of the Canton of Basel-Landschaft cancelled all
publicly held registered shares of Actelion Ltd (Actelion) with a nominal value
of CHFÂ 0.50 each (the Actelion Shares) based on article 137 of the Federal Act
on Financial Market Infrastructures and Market Conduct in Securities and
Derivatives Trading (Financial Market Infrastructure Act).
The holders of the cancelled Actelion Shares will be paid a cash compensation in
the amount of USDÂ 280 for each cancelled Actelion Share, corresponding to the
offer price paid by Janssen Holding GmbH, an indirect subsidiary of Johnson &
Johnson, in its public tender offer for all publicly held Actelion Shares. The
settlement and payment of the compensation to the remaining minority
shareholders of Actelion will take place on or around November 10, 2017.
By decision dated April 18, 2017, SIX Exchange Regulation approved the delisting
of the Actelion Shares from SIX Swiss Exchange. By decision dated October 30,
2017, SIX Exchange Regulation determined that the last day of trading of the
Actelion Shares will be November 6, 2017 and that the Actelion Shares will be
delisted from SIX Swiss Exchange on November 7, 2017.
###
NOTES TO EDITORS
About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of
Johnson & Johnson. We embrace research and science - bringing innovative ideas,
products and services to advance the health and well-being of people. Our
approximately 130,800 employees at more than 250 Johnson & Johnson operating
companies work with partners in health care to touch the lives of over a billion
people every day, throughout the world.
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to
create a world without disease. Transforming lives by finding new and better
ways to prevent, intercept, treat and cure disease inspires us. We bring
together the best minds and pursue the most promising science. We are Janssen.
We collaborate with the world for the health of everyone in it. Learn more at
www.janssen.com. Follow us at www.twitter.com/JanssenUS and
www.twitter.com/JanssenGlobal.
About Actelion Ltd
In June 2017, Actelion became part of the Janssen Pharmaceutical Companies of
Johnson & Johnson. Actelion's medicines help expand and strengthen Janssen's
portfolio with leading, differentiated in-market medicines and promising late-
stage compounds. Janssen has added Pulmonary Hypertension as a therapeutic area
of focus to maintain the leadership position Actelion has built in this
important disease area.
For further information please contact:
Investor Relations - Actelion Pharmaceuticals Ltd
+41 61 565 6565
www.actelion.com
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995 regarding the acquisition of
Actelion Ltd. The reader is cautioned not to rely on these forward-looking
statements. These statements are based on current expectations of future events.
If underlying assumptions prove inaccurate or known or unknown risks or
uncertainties materialize, actual results could vary materially from the
expectations and projections of Johnson & Johnson. Risks and uncertainties
include, but are not limited to: risks and uncertainties related to the ability
of the Johnson & Johnson family of companies to successfully integrate the
products, employees/operations and clinical work of Actelion, as well as the
ability to ensure continued performance or market growth of Actelion's products;
the potential that the expected benefits and opportunities of the transaction
may not be realized or may take longer to realize than expected; challenges
inherent in product research and development, including the uncertainty of
clinical success and obtaining regulatory approvals; uncertainty of commercial
success for new and existing products; competition, including technological
advances, new products and patents attained by competitors; adverse litigation
or government action; challenges to patents; changes to applicable laws and
regulations, including domestic and foreign health care reforms; changes in
behavior and spending patterns or financial distress of purchasers of health
care products and services; manufacturing difficulties and delays; product
efficacy or safety concerns resulting in product recalls or regulatory action;
and trends toward health care cost containment. A further list and description
of these risks, uncertainties and other factors and the general risks associated
with the respective businesses of Johnson & Johnson and Actelion can be found in
Johnson & Johnson's publicly available filings with the U.S. Securities and
Exchange Commission, and Actelion's publicly available filings on its website.
Copies of these filings, as well as subsequent filings, are available online at
www.sec.gov, www.jnj.com, www.actelion.com or on request from Johnson & Johnson.
Johnson & Johnson does not undertake to update any forward-looking statement as
a result of new information or future events or developments.
Medienmitteilung PDF:
http://hugin.info/131801/R/2145790/822635.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Sibanye-Stillwater: Versand eines Rundschreibens und Ankündigung der Hauptversammlung an die Aktionäre
Datum: 31.10.2017 - 07:00 Uhr
Sprache: Deutsch
News-ID 1546321
Anzahl Zeichen: 6943
Kontakt-Informationen:
Stadt:
Allschwil
Kategorie:
Wirtschaft (allg.)
Diese Pressemitteilung wurde bisher 0 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).